Anthropic releases Claude Science, sees Claude Code level impact
Brittany Trang, Ph.D., covers AI in health and medicine: Does it actually work? Who benefits, or might be…
Medicare obesity drug GLP-1 coverage starting July 1
Millions of older Americans in Medicare are about to receive a benefit that has never existed before: coverage…
Senator asks RFK Jr. if Eli Lilly’s mystery retatrutide patient is Trump
Lizzy leads STAT’s coverage of the FDA. Her stories explore the relationship between politics and science at the…
U.S. Treasury will oversee frozen Iranian funds when they’re released, Bessent says
The Treasury Department will oversee Iranian funds when they are released under President Donald Trump‘s interim Iran agreement,…
Eli Lilly gave mysterious access to weight loss drug to 79-year-old patient
Lizzy leads STAT’s coverage of the FDA. Her stories explore the relationship between politics and science at the…
FDA pilot program aims to speed up early-stage clinical trials
Lizzy leads STAT’s coverage of the FDA. Her stories explore the relationship between politics and science at the…
Lilly shares safety, tolerability data on its next-gen obesity drug
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected…
Revolution Medicines’ pancreatic cancer drug proving hard to get
Amy Johnston is distraught and readily admits that she is “grasping at straws.” Diagnosed last year with pancreatic…
New hormone protocol cut relapse risk in prostate cancer trial
Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of…
Revolution Medicines starts early access for pancreatic cancer drug
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
CVS restores Zepbound coverage, adds Eli Lilly’s obesity pill Foundayo
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on…
Eli Lilly: Single-shot gene therapy lowered cholesterol in early study
Eli Lilly said Monday that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in…